Traws Pharma (TRAW)
NASDAQ:TRAW

Traws Pharma (TRAW) Income Statement

1,798 Followers

Traws Pharma Income Statement

Last quarter (Q4 2023), Traws Pharma's total revenue was $56.00K, a decrease of 0.00% from the same quarter last year. In Q4, Traws Pharma's net income was $-4.98M. See Traws Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 226.00K$ 226.00K$ 226.00K$ 226.00K$ 231.00K$ 2.18M
Cost of Revenue
------
Gross Profit
$ 226.00K$ 226.00K$ 226.00K$ 226.00K--
Operating Expense
$ 21.27M$ 20.52M$ -19.85M$ -16.72M$ 25.22M$ 23.88M
Operating Income
$ -21.05M$ -20.30M$ -19.63M$ -16.50M$ -24.99M$ -21.70M
Net Non Operating Interest Income Expense
-$ 1.39M$ 651.00K---
Other Income Expense
$ -1.30M$ -1.35M$ -663.00K$ -333.00K$ -160.00K$ 206.00K
Pretax Income
$ -19.75M$ -18.95M$ -18.96M$ -16.16M$ -25.15M$ -21.49M
Tax Provision
----$ 4.00K$ 10.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -19.75M$ -18.95M$ -18.96M$ -16.16M$ -25.16M$ -21.50M
Basic EPS
$ -0.95$ -0.90$ -0.91$ -0.96$ -2.10$ -22.35
Diluted EPS
$ -0.95$ -0.90$ -0.91$ -0.96$ -2.10$ -22.35
Basic Average Shares
$ 83.99M$ 20.99M$ 20.91M$ 16.83M$ 11.60M$ 958.97K
Diluted Average Shares
$ 83.99M$ 20.99M$ 20.91M$ 16.83M$ 11.60M$ 958.97K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 21.27M$ 20.52M$ -19.85M$ -16.72M$ 25.22M$ 23.88M
Net Income From Continuing And Discontinued Operation
$ -19.75M$ -18.95M$ -18.96M$ -16.16M$ -25.16M$ -21.50M
Normalized Income
$ 1.70T$ -14.97M--$ -25.01M$ -21.55M
Interest Expense
------
EBIT
$ -19.75M$ -18.95M$ -18.96M$ -16.16M$ -24.99M$ -21.70M
EBITDA
$ -19.73M$ -18.93M$ -18.95M$ -16.15M$ -24.98M$ -21.68M
Currency in USD

Traws Pharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis